Hims & Hers stays attractive at $33 despite weak Q1, boosted by Novo Nordisk deal and growth plans.

Hims & Hers remains an appealing investment at $33 per share, supported by a renewed partnership with Novo Nordisk and unique access to patient demand. Although Q1 2026 results showed only 4% revenue growth, declining margins, and a net loss, the company's international expansion and diversified product categories strengthen its long-term outlook. Management aims for over $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, with valuation justified if customer retention and cross-selling improve. The company's ability to deepen customer relationships and meet its 2030 goals underpins a bullish investment case.